Stock ALZCUR ALZECURE PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

Other languages AlzeCure Pharma AB

Equities

ALZCUR

SE0010133785

Delayed Nasdaq Stockholm
Other stock markets
 10:14:24 22/05/2024 BST 		5-day change 1st Jan Change
2.04 SEK +2.00% Intraday chart for AlzeCure Pharma AB +14.29% -34.41%
05-14 AlzeCure Pharma AB Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors CI
04-25 AlzeCure Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AlzeCure Pharma AB Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors
AlzeCure Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024
Jan Lundberg acquired an unknown minority stake in AlzeCure Pharma AB (OM : ALZCUR).
AlzeCure Pharma AB Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024
AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at Leading Alzheimer's Conference
AlzeCure Pharma AB Publishes Clinical Results Supporting Continued Development of NeuroRestore ACD856 Against Alzheimer's
AlzeCure Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
AlzeCure Pharma AB Announces Live Expert Event on Alzheimer's Around Highly Current Gamma-Secretase Modulators
AlzeCure Pharma AB Gets Late Breaking Abstract of New Preclinical Data with ACD856 Accepted at AD/PD 2024 Conference
AlzeCure Pharma AB Selects Drug Candidate and Enters Next Phase of Development with Trka-Nam Acd137 Against Severe Pain
AlzeCure Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
AlzeCure Pharma AB Presents Disease-Modifying Data with NeuroRestore ACD856 At Alzheimer's Conference CTAD
AlzeCure Pharma AB Announces Japenese Patent Office Grants Patent Covering its Leading Candidate Drug ACD856
Alzecure Presents Clinical Phase Ii-Data with Acd440 for Neuropathic Pain At Pain Conference
AlzeCure Gets Presentation Accepted on Disease-Modifying Effects of Acd856 At Alzheimer's Conference
AlzeCure Pharma AB Presents Positive Phase II Clinical Data with ACD440 Against Neuropathic Pain at EFIC 2023 Conference
AlzeCure Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
AlzeCure Pharma Publishes the Positive Clinical Results from the Phase I Trial of NeuroRestore ACD856 Against Alzheimer's
AlzeCure Pharma AB Publishes New Disease Modifying Data with Neurorestore ACD856 Against Alzheimer's and Cognitive Disorders
AlzeCure Pharma AB Announces New Article on Antidepressive Effects with NeuroRestore ACD856
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALZCUR Stock
  4. News AlzeCure Pharma AB
  5. Other languages